Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laboratory for Advanced Medicine Inc.

www.lamoncogroup.com

Latest From Laboratory for Advanced Medicine Inc.

Laboratory For Advanced Medicine Appoints New CEO, Prepares To Scale Liquid Biopsy Pipeline

With a new CEO at its helm, Laboratory for Advanced Medicine is preparing to take on the cancer-diagnostics market. Former AncestryDNA executive Kenneth Chahine has joined the company as it plans to drive global commercialization of its artificial intelligence liquid biopsy pipeline.

Cancer Diagnostics

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

Cancer Personalized Medicine

Laboratory For Advanced Medicine (LAM) Appoints Chief Regulatory Officer

Liquid biopsy developer Laboratory for Advanced Medicine (LAM) named Jinjie Hu as chief regulatory officer.

Appointments Commercial

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

In Vitro Diagnostics Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Laboratory for Advanced Medicine Inc.
  • Senior Management
  • Kenneth Chahine, PhD, CEO
    Richard Brand, CFO
    Yinge Hu, PhD, CTO
  • Contact Info
  • Laboratory for Advanced Medicine Inc.
    Phone: (949) 333-1538
    9950 Research Dr.
    Irvine, CA 92618
    USA
UsernamePublicRestriction

Register